Johnson & Johnson (JNJ) announced last night its decision to discontinue the Phase 3 VENTURA development program evaluating aticaprant as ...

Johnson & Johnson (JNJ) stock in focus as company halts Phase 3 depression therapy trials for aticaprant over efficacy ...

Johnson & Johnson’s other depression drug Spravato (esketamine), in January, received FDA approval as the only monotherapy for adults living with major depressive disorder who have had an ...

Johnson & Johnson discontinues aticaprant's Phase 3 trial but explores future options. Another depression drug Spravato sales hit $1.01 billion ...

A depression drug candidate that’s a key part of Johnson & Johnson’s neuroscience strategy has failed a Phase 3 clinical trial, the latest dose of disappointing news for an emerging class of ...

Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of ...

The latest health news includes Johnson & Johnson halting testing on a depression drug, USDA eliminating food safety advisory ...

Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...

Johnson & Johnson (NYSE:JNJ) has decided to discontinue a Phase 3 program for its depression therapy aticaprant due to insufficient efficacy, the pharma giant announced. Known as VENTURA ...